BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND CHEK2, bA444G7, 11200, ENSG00000183765, O96017, RAD53, RP11-436C9_1, PP1425, LFS2, CHK2, HuCds1 AND Clinical Outcome
1011 results:

  • 1. Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
    Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
    Front Immunol; 2024; 15():1360615. PubMed ID: 38646521
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [
    Pruis IJ; Verburg FA; Balvers RK; Harteveld AA; Feelders RA; Vernooij MW; Smits M; Neggers SJCMM; Veldhuijzen van Zanten SEM
    J Nucl Med; 2024 May; 65(5):688-692. PubMed ID: 38514085
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The relationship between thyroid peroxidase antibody and differentiated thyroid cancer: a systematic review and meta-analysis.
    Zhang H; Tian L; Wang X; Shi X
    Front Endocrinol (Lausanne); 2024; 15():1349041. PubMed ID: 38476675
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma.
    Lippert J; Smith G; Appenzeller S; Landwehr LS; Prete A; Steinhauer S; Asia M; Urlaub H; Elhassan YS; Kircher S; Arlt W; Fassnacht M; Altieri B; Ronchi CL
    Eur J Endocrinol; 2024 Mar; 190(3):234-247. PubMed ID: 38451242
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian cancer.
    Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
    JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and clinical outcome in Pancreatic cancer.
    Blise KE; Sivagnanam S; Betts CB; Betre K; Kirchberger N; Tate BJ; Furth EE; Dias Costa A; Nowak JA; Wolpin BM; Vonderheide RH; Goecks J; Coussens LM; Byrne KT
    Cancer Immunol Res; 2024 May; 12(5):544-558. PubMed ID: 38381401
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Locally advanced pancreatic cancer: Is surgical palliation associated with improved clinical outcome relative to medical palliation?
    Kramer SP; Tonelli C; Luchette FA; Swanson J; Abdelsattar Z; Cohn T; Baker MS
    Am J Surg; 2024 Apr; 230():73-77. PubMed ID: 38350746
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
    Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
    Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.
    Schadeck J; Oberg HH; Peipp M; Hedemann N; Schamel WW; Bauerschlag D; Wesch D
    Front Immunol; 2023; 14():1286097. PubMed ID: 38259448
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer.
    Yang W; Chen H; Li G; Zhang T; Sui Y; Liu L; Hu J; Wang G; Chen H; Wang Y; Li X; Tan H; Kong R; Sun B; Li L
    J Transl Med; 2023 Dec; 21(1):903. PubMed ID: 38082307
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Subarachnoid hemorrhage due to pituitary adenoma apoplexy-case report and review of the literature.
    Yildiz Y; Lauber A; Char NV; Bozinov O; Neidert MC; Hostettler IC
    Neurol Sci; 2024 Mar; 45(3):997-1005. PubMed ID: 37872321
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. BRAF
    Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
    Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Optimal Follow-up of Incidental Pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
    Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
    Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
    La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
    Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
    Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
    Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
    Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 51.